MGO One Seven LLC Increases Stock Position in Astrazeneca Plc $AZN

MGO One Seven LLC grew its holdings in shares of Astrazeneca Plc (NYSE:AZN) by 10.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 51,051 shares of the company’s stock after purchasing an additional 4,627 shares during the period. MGO One Seven LLC’s holdings in Astrazeneca were worth $8,959,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Cornerstone Planning Group LLC boosted its stake in shares of Astrazeneca by 13.4% in the fourth quarter. Cornerstone Planning Group LLC now owns 993 shares of the company’s stock valued at $93,000 after buying an additional 117 shares in the last quarter. Binnacle Investments Inc grew its holdings in Astrazeneca by 21.8% during the third quarter. Binnacle Investments Inc now owns 660 shares of the company’s stock worth $51,000 after acquiring an additional 118 shares during the period. 44 Wealth Management LLC raised its position in Astrazeneca by 0.7% in the third quarter. 44 Wealth Management LLC now owns 16,722 shares of the company’s stock worth $1,283,000 after acquiring an additional 124 shares in the last quarter. CoreCap Advisors LLC raised its position in Astrazeneca by 30.6% in the third quarter. CoreCap Advisors LLC now owns 534 shares of the company’s stock worth $41,000 after acquiring an additional 125 shares in the last quarter. Finally, WPG Advisers LLC lifted its holdings in Astrazeneca by 6.2% in the fourth quarter. WPG Advisers LLC now owns 2,177 shares of the company’s stock valued at $200,000 after acquiring an additional 128 shares during the period. 20.35% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. DZ Bank upgraded shares of Astrazeneca from a “neutral” rating to a “buy” rating in a research report on Wednesday, April 29th. Sanford C. Bernstein reiterated a “buy” rating on shares of Astrazeneca in a report on Monday. Weiss Ratings started coverage on shares of Astrazeneca in a report on Wednesday, March 11th. They set a “buy (b)” rating on the stock. Deutsche Bank Aktiengesellschaft restated a “sell” rating on shares of Astrazeneca in a research report on Thursday, April 30th. Finally, Wall Street Zen raised shares of Astrazeneca from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. Twelve analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $205.33.

Astrazeneca Stock Down 1.2%

Astrazeneca stock opened at $182.67 on Friday. Astrazeneca Plc has a fifty-two week low of $132.32 and a fifty-two week high of $212.71. The firm has a market capitalization of $283.30 billion, a price-to-earnings ratio of 27.43, a price-to-earnings-growth ratio of 1.52 and a beta of 0.26. The stock’s fifty day moving average is $194.66 and its two-hundred day moving average is $180.88. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.71 and a current ratio of 0.91.

Astrazeneca (NYSE:AZN) last released its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.52 by $0.06. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%.The business had revenue of $15.29 billion during the quarter, compared to the consensus estimate of $14.93 billion. Analysts predict that Astrazeneca Plc will post 10.26 EPS for the current fiscal year.

Astrazeneca Dividend Announcement

The firm also recently announced a dividend, which was paid on Monday, March 23rd. Shareholders of record on Friday, February 20th were given a dividend of $1.595 per share. The ex-dividend date was Friday, February 20th. This represents a yield of 156.0%. Astrazeneca’s payout ratio is presently 65.17%.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.